Stock LALPATHLAB DR. LAL PATHLABS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Dr. Lal PathLabs Limited

Equities

LALPATHLAB

INE600L01024

Healthcare Facilities & Services

Market Closed - NSE India S.E.
Other stock markets
 12:43:53 27/06/2024 BST 		5-day change 1st Jan Change
2,748 INR +0.05% Intraday chart for Dr. Lal PathLabs Limited +2.57% +6.60%
05-14 Nomura Upgrades Dr. Lal Pathlabs to Buy From Neutral, Adjusts Price Target to INR2,713 From INR2,505 MT
05-13 Dr. Lal Pathlabs' Fiscal Q4 Consolidated Net Profit Rises; Share Up 6% MT

Valuation

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Capitalization 1 115,422 223,265 215,706 151,339 187,931 228,666 - -
Enterprise Value (EV) 1 108,088 213,412 212,332 145,552 180,959 218,042 214,370 211,635
P/E ratio 51.2 x 76.8 x 62.8 x 63.6 x 52.6 x 54.7 x 46.5 x 40.9 x
Yield 0.86% 0.52% 0.46% 0.66% 1.06% 0.74% 0.81% 1.01%
Capitalization / Revenue 8.68 x 14.1 x 10.3 x 7.5 x 8.44 x 9.16 x 8.15 x 7.31 x
EV / Revenue 8.12 x 13.5 x 10.2 x 7.22 x 8.13 x 8.73 x 7.64 x 6.77 x
EV / EBITDA 31.5 x 48.9 x 37.9 x 29.7 x 29.7 x 32 x 27.8 x 24.7 x
EV / FCF 45.6 x 58.9 x 60.2 x 34.7 x 37.4 x 43.6 x 36.9 x 32.4 x
FCF Yield 2.19% 1.7% 1.66% 2.88% 2.68% 2.29% 2.71% 3.09%
Price to Book 11.3 x 18.1 x 14.4 x 9.15 x 10.2 x 10.9 x 9.71 x 8.63 x
Nbr of stocks (in thousands) 82,344 82,475 82,624 82,785 83,051 83,213 - -
Reference price 2 1,402 2,707 2,611 1,828 2,263 2,748 2,748 2,748
Announcement Date 18/05/20 21/05/21 17/05/22 11/05/23 10/05/24 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Maart 2020 2021 2022 2023 2024 2025 2026 2027
Net sales 1 13,304 15,813 20,874 20,169 22,266 24,977 28,054 31,273
EBITDA 1 3,436 4,363 5,607 4,899 6,093 6,804 7,700 8,569
EBIT 1 2,708 3,591 4,526 3,397 4,657 5,273 6,077 6,819
Operating Margin 20.35% 22.71% 21.68% 16.84% 20.92% 21.11% 21.66% 21.8%
Earnings before Tax (EBT) 1 3,105 3,944 4,749 3,439 5,055 5,825 6,786 7,690
Net income 1 2,276 2,916 3,448 2,389 3,577 4,196 4,914 5,586
Net margin 17.11% 18.44% 16.52% 11.84% 16.06% 16.8% 17.52% 17.86%
EPS 2 27.37 35.25 41.57 28.74 42.98 50.28 59.03 67.26
Free Cash Flow 1 2,368 3,626 3,526 4,195 4,842 4,997 5,816 6,531
FCF margin 17.8% 22.93% 16.89% 20.8% 21.75% 20.01% 20.73% 20.88%
FCF Conversion (EBITDA) 68.92% 83.1% 62.88% 85.63% 79.47% 73.45% 75.54% 76.21%
FCF Conversion (Net income) 104.04% 124.34% 102.26% 175.6% 135.36% 119.1% 118.35% 116.91%
Dividend per Share 2 12.00 14.00 12.00 12.00 24.00 20.31 22.31 27.63
Announcement Date 18/05/20 21/05/21 17/05/22 11/05/23 10/05/24 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4 2026 Q1
Net sales 1 4,969 4,855 5,027 5,338 4,894 4,910 5,410 6,013 5,389 5,454 6,030 6,669 5,992 6,000 -
EBITDA 1 1,092 1,211 1,175 1,438 1,130 1,156 1,462 1,778 1,406 1,447 1,700 1,997 1,520 1,411 -
EBIT 1 785 834 816 1,050 751 780 1,111 1,419 1,046 1,081 1,290 1,593 1,161 1,093 -
Operating Margin 15.8% 17.18% 16.23% 19.67% 15.35% 15.89% 20.54% 23.6% 19.41% 19.82% 21.39% 23.89% 19.38% 18.22% -
Earnings before Tax (EBT) 1 815 835 814 1,028 765 832 1,175 1,522 1,159 1,199 1,448 1,852 1,253 1,084 -
Net income 1 573 613 577 717 528 567 826 1,093 813 845 1,059 1,332 916.6 793.6 -
Net margin 11.53% 12.63% 11.48% 13.43% 10.79% 11.55% 15.27% 18.18% 15.09% 15.49% 17.57% 19.97% 15.3% 13.23% -
EPS 2 6.900 7.380 6.960 8.600 6.350 6.820 9.930 13.12 9.760 10.12 14.01 16.00 11.21 9.544 -
Dividend per Share 2 - - - - - 12.00 - 6.000 - 6.000 - - - 18.36 -
Announcement Date 10/02/22 17/05/22 28/07/22 08/11/22 02/02/23 11/05/23 27/07/23 02/11/23 01/02/24 10/05/24 - - - - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Net Debt 1 - - - - - - - -
Net Cash position 1 7,334 9,853 3,374 5,787 6,972 10,623 14,295 17,030
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 2,368 3,626 3,526 4,195 4,842 4,997 5,816 6,531
ROE (net income / shareholders' equity) 23% 25.6% 25.1% 15.1% 20.3% 21.1% 21.5% 21.9%
ROA (Net income/ Total Assets) 18.5% 19.2% 17.2% 10.1% 14.8% 15.3% 17% -
Assets 1 12,324 15,178 20,071 23,661 24,208 27,424 28,908 -
Book Value Per Share 2 124.0 149.0 181.0 200.0 221.0 252.0 283.0 318.0
Cash Flow per Share 2 34.10 48.10 53.90 54.70 64.30 62.30 74.90 83.70
Capex 1 471 356 941 365 512 614 641 677
Capex / Sales 3.54% 2.25% 4.51% 1.81% 2.3% 2.46% 2.29% 2.16%
Announcement Date 18/05/20 21/05/21 17/05/22 11/05/23 10/05/24 - - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Dr. Lal PathLabs Limited

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
2,748 INR
Average target price
2,543 INR
Spread / Average Target
-7.47%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

1st Jan change Capi.
DR. LAL PATHLABS LIMITED Stock Dr. Lal PathLabs Limited
+6.60% 2.73B
SONIC HEALTHCARE LIMITED Stock Sonic Healthcare Limited
-17.80% 8.38B
RADNET, INC. Stock RadNet, Inc.
+68.91% 4.29B
SYNLAB AG Stock SYNLAB AG
-2.10% 2.62B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD. Stock Guangzhou Kingmed Diagnostics Group Co., Ltd.
-55.57% 1.85B
NEOGENOMICS, INC. Stock NeoGenomics, Inc.
-17.43% 1.7B
FLEURY S.A. Stock Fleury S.A.
-16.91% 1.43B
METROPOLIS HEALTHCARE LIMITED Stock Metropolis Healthcare Limited
+15.43% 1.19B
DIAN DIAGNOSTICS GROUP CO.,LTD. Stock Dian Diagnostics Group Co.,Ltd.
-49.10% 1.06B
ADICON HOLDINGS LIMITED Stock Adicon Holdings Limited
-23.54% 936M
Medical & Diagnostic Laboratories
  1. Stock Market
  2. Equities
  3. LALPATHLAB Stock
  4. Financials Dr. Lal PathLabs Limited